{"url_path":"/sec/rapp/8-k/2026-06-10/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-10","source_url":"https://www.sec.gov/Archives/edgar/data/2012593/0001193125-26-265841-index.html","accession_number":"0001193125-26-265841","cik":"0002012593","ticker":"RAPP","issuer_name":"Rapport Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/2012593/0001193125-26-265841-index.html","primary_entity_key":"0002012593","primary_entity_name":"Rapport Therapeutics, Inc."},"word_count":357,"has_tables":true,"body_markdown":"## Item 5.07 Submission of Matters to a Vote of Security Holders.\n\n \n\nOn June 10, 2026, Rapport Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). As of the close of business on April 14, 2026, the record date for the Annual Meeting, there were 47,807,623 shares of the Company’s common stock outstanding and entitled to vote at the Annual Meeting. The Company’s stockholders voted on the following matters, which are described in detail in the Company’s Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission on April 23, 2026: (i) to elect James Healy, M.D., Ph.D., Robert J. Perez, and Raymond Sanchez, M.D. as Class II directors of the Company, each to serve until the Company’s 2029 annual meeting of stockholders, and until his respective successor shall have been duly elected and qualified, or until his earlier death, resignation or removal (“Proposal 1”), and (ii) to ratify the appointment of PricewaterhouseCoopers LLP (“PwC”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 (“Proposal 2”).\n\n \n\n \n\nProposal 1 - Election of Class I Director Nominees\n\n \n\nThe Company’s stockholders approved the Class II director nominees recommended for election in Proposal 1 at the Annual Meeting. The results of Proposal 1 were as follows:\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nClass II Director Nominee\n\nFor\n\nWithheld\n\nBroker\nNon-Votes\n\nJames Healy, M.D., Ph.D.\n\n41,762,713\n\n587,163\n\n1,983,035\n\nRobert J. Perez\n\n37,592,089\n\n4,757,787\n\n1,983,035\n\nRaymond Sanchez, M.D.\n\n \n\n41,754,131\n\n \n\n595,745\n\n \n\n1,983,035\n\n \n\nProposal 2 - Ratification of Appointment of the Company’s Independent Registered Public Accounting Firm\n\n \n\nThe Company’s stockholders ratified the selection of PwC as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of Proposal 2 were as follows:\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nFor\n\nAgainst\n\nAbstain\n\n44,255,547\n\n57,445\n\n19,919\n\n \n\n \n\nNo other matters were submitted to or voted on by the Company’s stockholders at the Annual Meeting.\n\n \n\n \n\n \n\n \n\nSIGNATURE\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\n \n\nRapport Therapeutics, Inc.\n\n \n\n \n\n \n\n \n\nDate:\n\nJune 10, 2026\n\nBy:\n\n/s/ Troy Ignelzi\n\n \n\n \n\n \n\nTroy Ignelzi\nChief Financial Officer"}